Clinical Development

Publications and Posters

Scientific Publications

  1. Dietsch GN, Randall TD, Northfelt DW, et al. Late Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). Clin Cancer Res. 2015 Jul 7. pii: clincanres.0578.2015. [Epub ahead of print]
  2. Northfelt DW, Ramanathan RK, Cohen PA, et al. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res. 2014 Jul 15;20(14):3683-91.
  3. Lu H, Dietsch GN, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2012 Jan 15;18(2):499-509.
  4. Brueseke T, Tewari K. Toll-like Receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clinical Pharmacology: Advances and Applications 2013:5 (Suppl 1) 13–19
  5. Stephenson R, Chwee L, Matthews M, et al. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother (2013) 62:1347–1357
  6. Dowling DJ, Zhen T, et al. Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes. PLOS1. 2013;Volume 8, Issue 3
  7. Sacre S, Lo A, Gregory B, et al. Inhibitors of TLR Reduce TNF Production From Human Rheumatoid Synovial Membrane Cultures. J Immunol 2008; 181:8002-8009
  8. Saruta M, Targan S, Ling M, et al. High-frequency Haplotypes in the X Chromosome Locus TLR8 Are Associated with Both TC and UB in Female. Inflamm. Bowel Dis 2009; 15 (3):321-327
  9. Horak F. VTX-1463, A novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.

2016 Posters

  • A Phase 1b Study of Neoadjuvant Immune Biomarker Modulation with Cetuximab and Motolimod in Head and Neck Cancer (HNC). Shayan G, Kansy BA, Poveda Gibson S, et al.
    Presented at AHNS Annual Meeting, July 2016. Poster

2015 Posters

  • A Phase 1b Study of Neoadjuvant Immune Biomarker Modulation with Cetuximab and Motolimod in Head and Neck Cancer (HNC). Ferris R, Kansy B, Poveda Gibson S, et al.
    Presented at SITC Annual Meeting, November 2015. Poster
  • Motolimod, a Selective TLR8 Agonist, Induces Apoptosis in Monocytic Myeloid-derived Suppressor Cells (M-MDSC). Rutnam Z, Dang Y, Dietsch G, et al.
    Presented at SITC Annual Meeting, November 2015. Poster
  • A Phase 1b Study of Neoadjuvant Immune Biomarker Modulation with Cetuximab and Motolimod in Head and Neck Cancer (HNC). Kansy B, Gibson S, Srivastava R, et al.
    Presented at ASCO Annual Meeting, May 2015. Poster
  • Coordinated Activation of TLR8 and NLRP3 by VTX-2337 (Motolimod) Ignites Tumoricidal NK Cell Activity. Dietsch G, Lu H, Yang Y, et al.
    Presented at AACR Annual Meeting, April 2015. Poster

2014 Posters

  • Comparison of Immune Modulation by TLR8 Agonist VTX-2337 (Motolimod) in Cancer Patients and Healthy Volunteers. Dietsch G, Whiting S, Northfelt D, et al.
    Presented at SITC Annual Meeting, November 2014. Poster
  • (Trial in Progress) Active8: A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 (Motolimod) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). Ferris R, Cohen E, Gash K, et al.
    Presented at SITC Annual Meeting, November 2014. Poster
  • (Trial in Progress) Active8: a Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX 2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). Ferris R, Cohen E, Gash K, et al.
    Presented at IFHNOS/AHNS World Congress Meeting, July 2014. Poster
  • (Trial in Progress) Active8: a Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX 2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohen E, Ferris R, Gash K, et al.
    Presented at ASCO Annual Meeting, June 2014. Poster
  • Immune modulation by the TLR8 agonist VTX-2337; a comparison of the pharmacodynamic response in cancer patients and healthy volunteers. Deitsch G, Northfelt D, Ramanthan R, et al.
    Presented at the AACR Annual Meeting, April 2014. Poster
  • Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN). Chow LQM, Eaton KD, Baik C, et al.
    Presented at the Multidisciplinary Head and Neck Cancer Symposium, February 2014. Poster